Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XDS
|
|||
| Former ID |
DIB005747
|
|||
| Drug Name |
GSK-1070806
|
|||
| Synonyms |
Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-18 (IL18) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NOD-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Salmonella infection | ||||
| Legionellosis | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| Tuberculosis | ||||
| Influenza A | ||||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Toll receptor signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL12-mediated signaling events | ||||
| IL23-mediated signaling events | ||||
| Cellular roles of Anthrax toxin | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Interleukin-1 processing | |||
| WikiPathways | Hypertrophy Model | |||
| IL1 and megakaryotyces in obesity | ||||
| Corticotropin-releasing hormone | ||||
| NOD pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01648153) Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM. U.S. National Institutes of Health. | |||
| REF 2 | Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.